nach oben

Erschienen in:

01.08.2012 | original article

Characterization of the extended-spectrum b-lactamases and determination of the virulence factors of uropathogenic Escherichia coli strains isolated from children

verfasst von: Prof. Branka Bedenić, Prof. Jasmina Vraneš, Sabine Hofmann-Thiel, Ph.D., Prof. Marija Tonkić, Dr. Anita Novak, Viljemka Bučević-Popovic, Ph.D., Harald Hoffmann

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2012

Einloggen, um Zugang zu erhalten

Summary

Background and aim

The aim of the study was to characterize ESBL-producing uropathogenic Escherichia coli (UPEC) strains isolated in children. That included the investigation of virulence factors and the analysis of the types of β-lactamases at the molecular genetic level.

Material and methods

During the 2-year study period, 77 ESBL-producing E. coli strains were recovered from urine samples of febrile children with significant bacteriuria hospitalized at one Croatian hospital. Susceptibility of isolates to bactericidal serum activity was tested by Shiller and Hatch method, while adhesin expression was determined by agglutination methods. Characterization of ESBLs was performed by PCR with specific primers for ESBLs and by sequencing of bla _ESBL genes. Genotyping of the E. coli isolates was performed by pulsed-field gel electrophoresis (PFGE).

Results

Twenty-seven (35.1 %) and 50 (64.9 %) ESBL-producing UPEC strains were isolated in neonates and infants, respectively. Of 70 strains investigated for the presence of virulence factors, adhesins were detected in 48.6 % strains (8.6 % in the neonate and 40 % in the infants group) giving a statistically significant difference in adhesin expression between the two groups (p < 0.01). Hemolysin was produced by 84.3 %, whereas 70 % of strains were serum-resistant. The bla _TEM gene was detected in 22 (28 %) and bla _SHV gene in 57 strains (74 %), whereas bla _CTX-M gene was detected in only two isolates (2.5%). In ten isolates, bla _TEM and bla _SHV were simultaneously detected. Sequencing of bla _SHV genes revealed that SHV-5 β-lactamase was by far the most prevalent and was found in 51 strains (66 %). The strains were clonally related as demonstrated by PFGE and assigned into ten clusters.

Conclusions

Infection control measures should be employed and the consumption of expanded-spectrum cephalosporins in the hospital should be restricted.

Vorheriger Artikel Central venous to arterial pCO2 difference in cardiogenic shock

Nächster Artikel Is second eye phacoemulsification really more painful?

Bradford PA. Extended-spectrum b-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14:933–51.PubMedCrossRef

Jacoby GA, Munoz-Price LS. The new b-lactamases. N Engl J Med. 2005;352:380–92.PubMedCrossRef

Bonnet R. Growing group of extended-spectrum b-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother. 2004;48:1–14.PubMedCrossRef

Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum b-lactamases in the community. J Antimicrob Chemother. 2005;56:52–9.PubMedCrossRef

Pallecchi L, Bartoloni A, Fiorelli C, et al. Rapid dissemination and diversity of CTX-M extended-spectrum b-lactamase genes in commensal Escherichia coli isolates from healthy children from low resource settings in Latina America. Antimicrob Agents Chemother. 2007;51:2720–5.PubMedCrossRef

Lartigue MF, Zinsius C, Wenger A, Bille J, Poirel L, Nordman P. Extended-spectrum b-lactamases of the CTX-M type now in Switzerland. Antimicrob Agents Chemother. 2007;51:2855–60.PubMedCrossRef

Edelstein M, Pimkin M, Palagin I, Edelstein I, Stratchounski L. Prevalence and molecular epidemiology of CTX-M b-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian Hospitals. Antimicrob Agents Chemother. 2003;47:3724–32.PubMedCrossRef

Pournaras S, Ikonomidis A, Kristo I, Tsakris A, Maniatis A. CTX-M enzymes are the most common extended-spectrum b-lactamases among Escherichia coli in a tertiary Greek hospital. J Antimicrob Chemother. 2004;54:574–5.PubMedCrossRef

Canton R, Oliver A, Coque TM. Epidemiology of extended-spectrum b-lactamase-producing Enterobacter isolates in a Spanish hospital during a 12 year period. J Clin Microbiol. 2002; 40:1237–43.PubMedCrossRef

10.

Yamasaki K, Komatsu M, Yamashita T. Production of CTX-M-3 extended-spectrum b-lactamase and IMP-1 metallo-b-lactamase by five Gram-negative bacilli: survey of clinical isolates from seven laboratories collected in 1998 and 2000, in the Kinki region of Japan. J Antimicrob Chemother. 2003;51:631–8.PubMedCrossRef

11.

Yu WL, Winokur P, Von Stein DL. First description of CTX-M-β-lactamases (CTX-M-14 and CTX-M-3) in Taiwan. Antimicrob Agents Chemother. 2002; 46:1098–1100.PubMedCrossRef

12.

Chanawong A, M’Zalli FH, Heritage J. Three cefotaximases, CTX-M-9, CTX-M-13, and CTX-M-14 among Enterobacteriaceae in the People’s Republic of China. Antimicrob Agents Chemother. 2002;46:630–7.PubMedCrossRef

13.

Quinteros M, Radice M, Gardella N. Extended-spectrum b-lactamases in Buenos Aires, public hospitals. Antimicrob Agents Chemother. 2003;47:2864–7.PubMedCrossRef

14.

Calbo E, Romani V, Xercavins M, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum b-lactamases. J Antimicrob Chemother. 2006;57:780–3.PubMedCrossRef

15.

Delinska-Galinska A, Kurlenda J, Kozielska E, Borkowska A, Luczak G, Plata-Nazar K. Prevalence of ESBL strains in urinary tract infections in children in 1996 and 2004. Przegl Epidemiol. 2006;60:59–64.PubMed

16.

Uzunović-Kamberović S, Bedenić B, Vraneš J. Predominance of SHV-5 b-lactamase in community acquired urinary tract infections. Clin Microbiol Infect. 2007;13:820–3.PubMedCrossRef

17.

Hryniewicz K, Szczypa K, Sulikowska A, Jankowski K, Betlejewska K, Hryniewicz W. Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J Antimicrob Chemother. 2007;47:773–80.CrossRef

18.

Vranes J, Kruzic V, Sterk-Kuzmanovic N, Schoenwald S. Virulence characteristics of Escherichia coli strains causing asymptomatic bacteriuria. Infection 2003;31:216–20.PubMed

19.

Vranes J. Hemagglutination ability and adherence to the Buffalo green monkey kidney cell line of uropathogenic Escherichia coli. APMIS. 1997;105:831–7.PubMedCrossRef

20.

Schiller NL, Hatch RA. The serum sensitivity, colony morphology, serogroup specificity, and outer membrane protein of Pseudomonas aeruginosa strains isolated from several clinical sites. Diagn Microbiol Infect Dis. 1983;1:145–7.PubMedCrossRef

21.

CLSI. Performance standards for antimicrobial susceptibility testing methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Eighteen informational supplement. CLSI document M100-S18. Wayne: Clinical and Laboratory Standards Institute; 2008.

22.

Rasheed JK, Anderson GJ, Yigit H, et al. Characterization of the extended-spectrum b-lactamase reference strain, Klebsiella pneumoniae K6, (ATCC 700603) which produces the novel enzyme SHV-18. Antimicrob Agents Chemother. 2000;44:2382–8.PubMedCrossRef

23.

Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum b-lactamases conferring transferable resistance to newer b-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis. 1988;10:867–78.PubMedCrossRef

24.

Elwell LP, Falkow S. The characterization of R plasmids and the detection of plasmid-specified genes. In: Lorian V editor. Antibiotics in laboratory medicine. 2nd edn. Baltimore: Williams and Wilkins; 1986. p. 683–721.

25.

Nüesch-Inderbinen MT, Hächler H, Kayser FH. Detection of genes coding for extended-spectrum SHV b-lactamases in clinical isolates by a molecular genetic method, and comparison with the E test. Eur J Clin Microbiol Infect Dis. 1996;15:398–402.PubMedCrossRef

26.

Arlet G, Brami G, Decre D, Flippo A, Gaillot O, Lagrange PH, Philippon, A. Molecular characterization by PCR restriction fragment polymorphism of TEM b-lactamases. FEMS Microbiol Lett. 1995;134:203–8.PubMed

27.

Woodford N, Ward ME, Kaufmann ME, et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum b-lactamases in the UK. J Antimicrob Chemother. 2006;54:735–43.CrossRef

28.

Pagani L, Mantengoli E, Migliavacca R, et al. Multifocal detection of multidrug-resistant Pseudomonas aeruginosa producing PER-1 extended-spectrum b-lactamase in Northern Italy. J Clin Microbiol. 2004;42:2523–9.PubMedCrossRef

29.

Woodford N, Fagan, EJ, Ellington, MJ. Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum b-lactamases. J Antimicrob Chemother. 2006; 57:154–5.PubMedCrossRef

30.

Kaufman ME. Pulsed-field gel electrophoresis. In: Woodfor N, Johnsons A, editors. Molecular bacteriology. Protocols and clinical applications. 1st edn. New York: Humana Inc. Totowa; 1998. p. 33–51.

31.

Tenover F, Arbeit R, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbio. 1995;2233–9.

32.

Empel J, Baraniak A, Literacka E, et al. Molecular survey of b-lactamases conferring resistance to newer b-lactams in Enterobacteriaceae isolates from Polish hospitals. Antimicrob Agents Chemother. 2008; 52:2449–54.PubMedCrossRef

33.

Lee J, Pai H, Kim Y, et al. Control of extended-spectrum b-lactamase producing Escherichia coli and Klebsiella pneumoniae in a children’s hospital by changing antimicrobial agent usage policy. J Antimicrob Chemother. 2007;60:629.PubMedCrossRef

34.

Tonkić M, Goić-Barišić I, Punda-Polić V. Prevalence and antimicrobial resistance of extended-spectrum b-lactamase producing Escherichia coli and Klebsiella pneumoniae in a University Hospital Split. Int Microbiol. 2005; 8:119–24.PubMed

35.

Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G. Italian ESBL study group Occurrence of extended-spectrum b-lactamases in members of the family Enterobacteriaceae in Italy: implication for resistance to b-lactams and other antimicrobial drugs. Antimicrob Agents Chemother. 2002;46:196–202.PubMedCrossRef

36.

Goosens H. Mystic program: summary of European data from 1997–2000. Diagn Microbiol Infect Dis. 2001;41:183–9.CrossRef

37.

Yu Y, Zhou W, Chen Y, Ding Y, Ma Y. Epidemiologic and antibiotic resistance study on extended-spectrum b-lactamase producing Escherichia coli and Klebsiella pneumoniae in Zhejinang Province. Chin Med J. 2002;115:1479–82.PubMed

38.

Gales AC, Sader HH, Jones RH. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America; frequency of occurrence and antimicrobial susceptibility profile: results from SENTRY Antimicrobial Resistance Program (1997–2000). Diagn Microbiol Infect Dis. 2002; 44:301–11.PubMedCrossRef

39.

Tash H, Hakki-Bahar I. Molecular characterization of TEM and SHV-derived extended-spectrum b-lactamases in hospital-based Enterobacteriaceae in Turkey. Jpn J Infect Dis. 2005;58:162–7.

40.

Prodinger WM, Fille M, Bauernfeind A, et al. Molecular epidemiology of Klebsiella pneumoniae producing SHV-5 b-lactamase: parallel outbreaks due to multiple plasmid transfer. J Clin Microbiol. 1996;34:564–8.PubMed

41.

Bauernfeind A, Rosenthal E, Eberlein E, Holley M, Schweighart S. Spread of Klebsiella pneumoniae producing SHV-5 b-lactamase among hospitalized patients. Infection 1993;21:24–8.CrossRef

42.

Pragai Z, Koczian Z, Nagy E. Characterization of the extended-spectrum b-lactamases and determination of the antibiotic susceptibilities of Klebsiella pneumoniae isolates in Hungary. J Antimicrob Chemother. 1998;42:401–3.PubMedCrossRef

43.

Gniadkowski M, Schneider I, Jungwirth R, Hryniewicz W, Bauernfeind A. Ceftazidime-resistant Enterobacteriaceae isolates from three Polish hospitals: identification of three novel TEM- and SHV-5 type extended-spectrum b-lactamases. Antimicrob Agents Chemother. 1998;4:514–20.

44.

Vatopoulos AC, Philippon A, Tzouvelekis LS, Komninou Z, Legakis NJ. Prevalence of a transferable SHV-5 type b-lactamase in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Greece. J Antimicrob Chemother. 1990;26:635–48.PubMedCrossRef

45.

Miranda G, Castro N, Leanos B, Valenzuela A, Garza-Ramos U, Rojas T, et al. Clonal and horizontal dissemination of Klebsiella pneumoniae expressing SHV-5 extended-spectrum b-lactamase in a Mexican Pediatric hospital. J Clin Microbiol. 2004;42:30–5.PubMedCrossRef

46.

Bedenic B, Randegger C, Stobberingh E, Haechler H. Molecular epidemiology of extended-spectrum β-lactamases from Klebsiella pneumoniae strains, isolated in Zagreb, Croatia. Eur J Clin Microbiol Infect Dis. 2001;20:505–8.

47.

Bedenic B, Schmidt H, Herold S, et al. Spread of Klebsiella pneumoniae producing SHV-5 b-lactamase in Dubrava University Hospital, Zagreb. J Chemother. 2005;17:367–75.

48.

Vranić-Ladavac M, Bošnjak Z, Beader N, Barišić N, Kalenić S, Bedenić B. Clonal spread of CTX-M producing Klebsiella pneumoniae in Croatian hospital. J Med Microbiol. 2010;59:1069–78.PubMedCrossRef

49.

Bedenić B, Vraneš J, Bošnjak Z, Marijan T, Mlinarić-Džepina A, Kukovec T, Anušić M, Beader N, Barl P, Leskovar V, Kalenić S. Emergence of CTX-M group 1 extended-spectrum b-lactamase-producing Klebsiella pneumoniae strains in the community. Med Glas. 2010;1:32–9.

50.

Payne DJ, Marriot MS, Amyes SGB. Characterization of a unique ceftazidime-hydrolyzing b-lactamase, TEM-E2. J Med Microbiol. 1990;12:131–4.CrossRef

51.

Essack S. Treatment options for extended-spectrum b-lactamase producers. FEMS Microbiol Lett. 2000;190:181–4.PubMed

Titel: Characterization of the extended-spectrum b-lactamases and determination of the virulence factors of uropathogenic Escherichia coli strains isolated from children
verfasst von: Prof. Branka Bedenić
Prof. Jasmina Vraneš
Sabine Hofmann-Thiel, Ph.D.
Prof. Marija Tonkić
Dr. Anita Novak
Viljemka Bučević-Popovic, Ph.D.
Harald Hoffmann
Publikationsdatum: 01.08.2012
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 15-16/2012
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-012-0210-5

Springer Medizin Österreich

Summary

Background and aim

Material and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 15-16/2012

Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock

Is second eye phacoemulsification really more painful?

Serum lactate level predict mortality in elderly patients with cirrhosis

Therapie des kastrationsrefraktären Prostatakarzinoms

Central venous to arterial pCO2 difference in cardiogenic shock

Smoking and lung cancer: current trends in Austria